Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients
Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This prospective, single center, phase II study is to evaluate the efficacy and safety of
bicalutamide as a treatment in androgen receptor (AR)-positive metastatic triple-negative
breast cancer (mTNBC) patients.